Houston software startup is tapping into the military sector with VR training tools

Houston innovators podcast episode 127

Scott Schneider of HTX Labs joins the Houston Innovators Podcast to discuss how his VR software is helping to train Department of Defense pilots. Photo via htxlabs.com

For years, the idea of virtual and augmented reality has been growing in use and popularity from a consumer perspective. VR art experiences are popping up in every major city, and Snapchat and Instagram filters are flooding our phone screens daily. But one Houston company had the foresight to tap this tech in the business world.

"Our real mission around HTX Labs was to take what we felt was amazing technology — virtual reality, augmented reality, extended reality, and immersive technology in general — and take it from a primary consumer focus into enterprise," Scott Schneider says on this week's episode of the Houston Innovators Podcast.

A VR headset is different from your usual office appliance — it's not a printer or a desktop computer. So, addressing this technology and how companies deal with network security and identity management — plus the software designing itself — has been HTX Labs' bread and butter since it was founded in 2017.

"It's always been around how do we elevate training — and that's really been our mission for the past five years," Schneider says.

Over the years, the startup has had the opportunity to enter a new sector, and it's represented a pretty big pivot for the company. Now, 95 percent of HTX Labs's focus is on the Department of Defense.

"Around 2018, we were approached by the U.S. Air Force," Schneider says. "Three and a half years later, we are fully engaged with the DoD – Air Force, Navy, Army. Our big focus is around training aircraft pilots and maintainers — if you fly them or you fix them, they are using our technology."

HTX Labs has tripled its team over the past few years, and is looking to hire another 20 people to support its growth — specifically looking for sales, business development, and operational positions.

"In 2021, we were all about building capability and building our platform," Schneider says, "and 2022 is all about adoption. It's a land grab out there for doing what we're doing. We're trying to drive adoption within the government and outside in the commercial and private sector."

Schneider shares more on what he's focused on this year and how HTX Labs has grown alongside the Houston innovation ecosystem on the podcast episode. Listen to the full interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Houston-based Pulmotect announced a grant from the U.S. Department of Defense that will fund two COVID-19 drug trials. Photo via Getty Images

Houston biotech receives up to $6M federal grant for COVID-19 treatment

DOD delivered

The Pentagon is putting its financial power behind two COVID-19 clinical trials led by Houston-based biotech company Pulmotect Inc.

The U.S. Department of Defense is pumping as much as $6 million into the pair of Phase 2 trials, which involve a total of 300 U.S. participants, according to a January 27 news release from Pulmotect. When it's inhaled, Pulmotect's drug, PUL-042, stimulates the lungs' immune system to fight bacteria, viruses, or fungi that cause respiratory illnesses.

Pulmotect joins a number of Houston organizations that have tapped into Department of Defense funding for research into COVID-19 therapies.

In January, for instance, researchers at the University of Texas Health Science Center at Houston (UTHealth) collected $5.1 million from the department to evaluate whether an investigational oral drug, vadadustat, can help prevent acute respiratory distress syndrome (ARDS) in COVID-19 patients.

"It's wonderful that we have COVID-19 vaccinations available now, but they won't directly help patients who are already sick in the hospital or who will become sick in the future," Dr. Holger Eltzschig, chairman of Department of Anesthesiology at UTHealth's McGovern Medical School, says in a news release.

Also in January, Houston-based clinical research organization Pharm-Olam LLC sealed a $36.3 million deal with the Department of Defense to conduct a clinical trial of an antibody treatment for inflammatory problems associated with COVID-19.

So far, Pulmotect's PUL-042 has shown promise in battling the coronaviruses that trigger MERS (Middle East respiratory syndrome) and SARS (severe acute respiratory syndrome). The current trials related to the coronavirus that causes COVID-19 are evaluating PUL-042's effect on prevention of infections and reducing the severity of the disease.

Pulmotect initially designed PUL-042 to treat and prevent respiratory complications in cancer patients. But once the coronavirus pandemic set in, the company pivoted to testing the effectiveness of its drug in combatting the virus that causes COVID-19. Last May, the U.S. Food and Drug Administration (FDA) approved Pulmotect's COVID-19 trials.

Pulmotect says PUL-042 someday could be a therapy that's deployed during pandemics, epidemics, and bioterrorism attacks.

Invented at Houston's MD Anderson Cancer Center and at Texas A&M University, PUL-042 has earned patents in 10 countries. The National Institutes of Health, the Cancer Prevention and Research Institute of Texas, and other organizations have supported R&D for PUL-042.

Founded in 2007, Pulmotect emerged from Houston's Fannin Innovation Studio, which nurtures early stage companies in the life sciences sector. In September 2019, the company brought aboard Dr. Colin Broom as CEO. He previously was CEO of an Irish biopharmaceutical company.

Thus far, Pulmotect has garnered about $18 million in equity and about $20 million in other funding.

Before the pandemic, Pulmotect was evaluating the effectiveness of PUL-042 in treating patients with mild chronic obstructive pulmonary disease (COPD) who've been exposed to a respiratory virus.

COPD, which affects 30 million Americans, is the No. 3 cause of death in the U.S., according to the COPD Foundation. Pulmotect says 40 percent of COPD-related costs could be avoided by heading off complications and hospitalizations, which usually result from COPD problems caused by a bacterial or viral infection. In this context, the drug is meant to treat cancer patients undergoing chemotherapy whose weakened immune systems make them susceptible to pneumonia.

Ad Placement 300x100

Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston Innovation Awards opens ticket sales as nomination deadline looms

mark your calendar

You can now buy tickets to the 2023 Houston Innovation Awards on November 8 — but the deadline to nominate deserving individuals and companies for the prestigious awards is just a few days away.

Tickets are available online for the awards event taking place at Silver Street Studios, and InnovationMap has a few options to choose from. Individual tickets are on sale for $80, with a special founder price of $40 available. This year, individual tickets will have seating at a first come, first served basis, but attendees are also able to opt into a reserved table of 10 for $1,000. Sponsors, judges, and finalists and their guests will receive complimentary tickets.

The nomination period for the annual awards is coming to a close next week on Tuesday, September 19. Click here to read about this year's awards categories.The process includes submitting nominations on behalf of yourself or others, and next week, nominees will be sent an application that will be due October 4. A panel of judges will review the applications and finalists will be announced and notified ahead of the event.

If you are interested in joining our partners, which include The Ion, Uncle Nearest Premium Whiskey, Tito’s Handmade Vodka, and more, in sponsoring this event, please reach out to misti@gowmedia.com.

Secure your Houston Innovation Awards tickets now.

Submit a nomination before it's too late!

Cultivating an office culture can prevent loneliness, create connections, says Houston expert

guest column

There’s been a lot of chatter about returning to the office and remote work. No matter which side of the argument you’re on, there are valid points to be made for both views. The pandemic forced organizations to rethink operations, with many employees working remote for the first time. And now, we’re in that habit and many don’t want to change.

But here’s the thing. Isolation creates loneliness and we’re in the middle of a loneliness epidemic. A report released by The U.S. Surgeon General titled “Our Epidemic of Loneliness and Isolation,” found that even before COVID changed the world, about half of the U.S. adults reported experiencing measurable levels of loneliness. While technology has allowed for work to continue outside of traditional office walls by dialing in to video conferences from home, there is still a missing link. It’s much harder to build community virtually. We haven’t cracked that code yet.

Sen. Chris Murphy, D – Conn, recently introduced legislation to create a national policy to promote social connection and address the soaring rates of loneliness.

“Loneliness is one of the most serious, misunderstood problems facing America today,” Murphy said in a press statement. “This crisis transcends traditional political boundaries, presenting a chance to bring together right and left around a project to help people find connectedness.”

Whether people realize it or not, we all need to feel seen and understood, and when that happens it creates meaningful connection. That connection in turn leads to strong company Whether people realize it or not, we all need to feel seen and understood, and when that happens it creates meaningful connection. That connection in turn leads to strong company culture and more productive, energizing workdays.

Happiness begins with healthy human relationships and companies are being challenged to balance employee flexibility and workplace interactions. While there is no clear-cut right answer, Birkman International is moving to a four-day, in-office workweek. Employees will cut back from 40 to 32 hours-per-week and those hours will be spent at Birkman’s offices.

With employees once again working under the same roof, there will be opportunities for organic spot meetings, team brainstorms and water cooler chatter. While some might see these as “soft” skills, they are essential for a well-performing workplace.

It’s important to remember that there’s no one-size-fits-all solution to balancing employee flexibility with returning to the office. Just like every person has unique needs, every company must figure the best solution for its culture, its productivity and most importantly, its people.

------

Amy Shepley serves as president at Birkman International, an industry-leading organizational performance company.

Houston startup with sustainable biotech solutions lands offtake arrangement with United Airlines

ready for takeoff

An innovative Houston company is celebrating a new deal with a global airline.

Cemvita Corp. announced a new offtake arrangement with United Airlines. Cemvita's first full-scale sustainable aviation fuel plant will provide up to 1 billion gallons of SAF to United Airlines. The 20-year contract specifies that Cemvita will supply up to 50 million gallons annually to United.

It's not the first collaboration Cemvita has had with the airline. Last year, United invested in the biotech company, which used the funding to open its Houston pilot plant.

“Since our initial investment last year, Cemvita has made outstanding progress, including opening their new pilot plant – an important step towards producing sustainable aviation fuel,” United Airlines Ventures President Michael Leskinen says in a news release. “United is the global aviation leader in SAF production investment, but we face a real shortage of available fuel and producers. Cemvita’s technology represents a path forward for a potentially significant supply of SAF and it’s our hope that this offtake agreement for up to one billion gallons is just the beginning of our collaboration.”

Founded in Houston in 2017 by brother-sister team Moji and Tara Karimi, Cemvita's biotechnology can mimic the photosynthesis process, turning carbon dioxide into feedstock. The company's SAF plan hopes to increase reliability of existing SAFs and lower impact of fuel creation.

“Biology is capable of truly amazing things,” Moji Karimi, CEO of Cemvita, says in the release. “Our team of passionate, pioneering, and persistent scientists and engineers are on a mission to create sustainable BioSolutions that redefine possibilities.”

“We are thrilled to partner with United Airlines in working towards transforming the aviation industry and accelerating the energy transition,” he continues. “This agreement featuring our unique SAF platform is a major milestone towards demonstrating our journey to full commercialization.”

Earlier this year, United, which was reportedly the first airline to announce its goal of net zero carbon emissions by 2050, launched its UAV Sustainable Flight FundSM. The fund, which named Cemvita to its inaugural group of portfolio companies, has raised over $200 million, as of this summer.

Moji and Tara Karimi co-founded Cemvita in 2017. Photo courtesy of Cemvita